ArticleOncogene2004
Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- IKIP downregulates THBS1/FAK signaling to suppress migration and invasion by glioblastoma cells.Oncology research · 2024Article
- Thrombospondin-2 promotes the proliferation and migration of glioma cells and contributes to the progression of glioma.Chinese neurosurgical journal · 2022Article
- Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?International journal of molecular sciences · 2022Review
- Thrombospondin-1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma.Oncology letters · 2021Article
- Deciphering the complex role of thrombospondin-1 in glioblastoma development.Nature communications · 2019Article
- CD36 tango in cancer: signaling pathways and functions.Theranostics · 2019Review
- Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.International journal of molecular sciences · 2013Review
- Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Estrogen regulation of thrombospondin-1 in human breast cancer cells.International journal of cancer · 2009Article
- Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.Current drug targets · 2008Review
- Antiangiogenic therapy in brain tumors.Expert review of neurotherapeutics · 2008Review
- New molecular targets in angiogenic vessels of glioblastoma tumours.Expert reviews in molecular medicine · 2008Review
- Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1.Oncogene · 2006Article
- The role of the extracellular matrix in angiogenesis in malignant glioma tumors.Brain pathology (Zurich, Switzerland) · 2005Review
- Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.Neuro-oncology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are among the most malignant and most highly vascularized human tumors. We studied the therapeutic action of an angiostatic fragment of human thrombospondin 1 (named TSP1ang) on experimental glioma tumor growth. TSP1ang (enclosing amino acids 167-569) comprised the procollagen-homology domain and the three type I repeats of the original molecule. C6 glioma cells that stably express TSP1ang were generated, and their rate of in vitro growth did not appear to differ from that of C6 cells transfected with an empty plasmid. TSP1ang-expressing C6 cells were then injected either subcutaneously or intracerebrally into nude mice. The resulting tumors appeared to be less vascularized, but unexpectedly started to grow earlier and had a much more invasive phenotype than tumors derived from control C6 cells. They were also much more aggressive, since the mice bearing intracerebral TSP1ang-expressing tumor cells died before day 19 post-implantation, whereas all mice bearing control C6 tumors were alive at this time point. These results indicate that careful attention should be paid at designing smaller fragments from the multimodular angiostatic molecule TSP1 since, as observed in this study, it may unmask protumorigenic properties that counteract its antiangiogenic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.